

---

## **BiBBInstruments AB – The subscription period for warrants of series TO 1 begins today**

The subscription period for the warrants of series TO 1 ("Warrants" or "TO 1") that BiBBInstruments AB ("BiBB" or the "Company") issued in connection with the Company's rights issue of units, the subscription period of which ended during the first quarter of 2025 (the "Rights Issue"), begins today. The subscription period is on-going until and including June 5, 2025. One (1) Warrant entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 3.25.

### **The Warrants in summary**

BiBB issued a total of 2,755,282 Warrants in connection with the Rights Issue. In accordance with the terms for the TO 1, holders are entitled, during the period from today, May 22, 2025, until and including June 5, 2025, to subscribe for one (1) new share in BiBB for each one (1) Warrant held. The subscription price is SEK 3.25.

If all Warrants are exercised for the subscription of new shares in BiBB, the Company will receive approximately SEK 9.0 million before issue costs.

In order for the Warrants not to expire without value, the holder must actively exercise the Warrants to subscribe for new shares in the Company no later than June 5, 2025, or sell the Warrants no later than June 3, 2025. Please note that custodians may close the subscription period prior June 5, 2025, and holders who have their holdings of TO 1 registered with a custodian are therefore advised to contact their custodian at an early stage to receive information about the period that applies for the exercise of TO 1.

Complete terms and conditions for the Warrants are available on the Company's website: [www.bibbinstruments.com/](http://www.bibbinstruments.com/).

### **The Warrants terms in summary**

Terms: One (1) Warrant of series TO 1 entitles to subscribe for one (1) new share in the Company.

Subscription price: SEK 3.25 per share, no commission is payable.

Exercise period: May 22, 2025 until June 5, 2025.

Last day for trading with TO 1: June 3, 2025.

Shares, share capital and dilution: Upon full exercise of the Warrants, the share capital will increase with SEK 234,198.97, from SEK 3,419,072.81 to SEK 3,653,271.78 and the number of shares will increase with 2,755,282 shares, which means that the total number of shares will increase from 40,224,386 shares to 42,979,668 shares. The dilution upon full exercise of the Warrants amounts to approximately 6.4 percent of the number of shares and votes in the Company.

---

How to exercise the Warrants:

**Custodian-registered Warrants:**

Subscription and payment through the exercise of the Warrants shall be made in accordance with the instructions from the respective custodian. Please contact your custodian for further information. Note that custodians may have an earlier response date for the subscription of shares through the exercise of Warrants. Holders who have their holdings of TO 1 registered with a custodian are therefore advised to contact their custodian at an early stage.

**Directly registered Warrants (VP account):**

Subscription shall be made by simultaneous cash payment according to the instructions on the application form distributed to directly registered holders. The application form will also be available on the Company's website ([www.bibbinstruments.com](http://www.bibbinstruments.com)).

**Advisors**

DNB Carnegie SME and Setterwalls Advokatbyrå AB acted financial and legal advisors to BiBB in connection with the Rights Issue.

*This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.*

**For more information about BiBB, please contact:**

Fredrik Lindblad, CEO

E-mail: [fredrik.lindblad@bibbinstruments.com](mailto:fredrik.lindblad@bibbinstruments.com)

Phone: +46 70 899 94 86

[www.bibbinstruments.com](http://www.bibbinstruments.com)

---

**About BiBB**

BiBBInstruments AB ("BiBB") develops and manufactures EndoDrill® – the world's first market-cleared, powered biopsy instrument for endoscopy. EndoDrill® enables rapid and high-quality core needle biopsies (CNB) for the diagnosis of serious cancers, including gastric, pancreatic, liver, lung, and bladder cancer. The product portfolio targets the fast-growing global market for endoscopic ultrasound-guided biopsy instruments (EUS/EBUS). EndoDrill® GI is FDA-cleared and CE-marked, with U.S. launch starting in 2025 in collaboration with TaeWoong Medical USA. EndoDrill® EBUS and URO were CE-marked in 2024 and are planned for gradual launch. BiBB was founded by Dr Charles Walther and is headquartered at Medicon Village in Lund, Sweden. The share (BiBB) is listed on Spotlight Stock Market.

**IMPORTANT INFORMATION**

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in BiBB. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in BiBB has only been made through the prospectus published by BiBB on December 19, 2024.